# A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

> **NCT03661138** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 272 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo for upadacitinib
- **DRUG:** Topical Corticosteroids (TCS)

## Key facts

- **NCT ID:** NCT03661138
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-27
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03661138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03661138, "A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03661138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*